The market has been high on Actinium Pharmaceuticals Inc (ATNM) stock recently. ATNM gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator.
What is Stock Sentiment?
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.
InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.
Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .
What's Happening With ATNM Stock Today?
Actinium Pharmaceuticals Inc (ATNM) stock is down -2.38% while the S&P 500 is up 1.36% as of 11:57 AM on Tuesday, Nov 17. ATNM is down -$0.30 from the previous closing price of $12.63 on volume of 434,189 shares. Over the past year the S&P 500 is higher by 14.83% while ATNM is up 94.79%. ATNM lost -$2.59 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Actinium Pharmaceuticals Inc click here.
More About Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Click Here to get the full Stock Score Report on Actinium Pharmaceuticals Inc (ATNM) Stock.
